<DOC>
	<DOCNO>NCT01215188</DOCNO>
	<brief_summary>This study evaluate whether aluminum-adjuvanted non-adjuvanted formulation candidate pneumococcal vaccine ( V114 ) non-inferior Prevnar 13™ base immune response 13 serotypes common Prevnar 13™</brief_summary>
	<brief_title>A Study Pneumococcal Conjugate Vaccine ( V114 ) Compared Marketed Vaccine ( V114-003 AM2 )</brief_title>
	<detailed_description>A primary reason study amend extend comparison V114 Prevnar 13™ 13 serotypes common , evaluate response dose 4 primary outcome measure .</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion : Healthy infant , age ≥ 6 ≤ 12 week ( ≥ 42 day ≤ 89 day ) . Participant 's parent/legal guardian understands study procedure , alternate treatment available risk involve study , voluntarily agree allow child participate give write informed consent . Afebrile , rectal temperature &lt; 38.1°C ( &lt; 100.5°F ) axillary temperature &lt; 37.8°C ( &lt; 100.0°F ) day vaccination . Participant 's parent/legal guardian able read , understand , complete study questionnaire ( i.e. , Vaccination Report Card ) . Participant able attend schedule visit comply study procedure . Participant 's parent/legal guardian access telephone . Prior administration pneumococcal vaccine . Known hypersensitivity component pneumococcal conjugate vaccine . Known suspected impairment immunological function . Participant history congenital acquire immunodeficiency ( e.g. , splenomegaly ) . Participant his/her mother document human immunodeficiency virus ( HIV ) infection . Functional anatomic asplenia . History autoimmune disease include multiple sclerosis ( MS ) , systemic lupus , polymyositis , inclusion body myositis , dermatomyositis , Hashimoto 's thyroiditis , Sjogren 's syndrome , rheumatoid arthritis , autoimmune disorder . Known neurologic cognitive behavioral disorder include multiple sclerosis ( MS ) , MSlike disease , encephalitis/myelitis , acute disseminate encephalomyelitis , pervasive developmental disorder , related disorder . Use immunosuppressive therapy ( Note : topical inhaled/nebulized steroid permit ) . Participants intramuscular , oral , intravenous corticosteroid treatment exclude receive expect receive period 30 day prior Visit 1 Visit 6 ( 30 day postdose 4 ) 2 mg/kg per day prednisone ( equivalent ) , 20 mg/d weigh 10 kg otherwise immunocompromised . Excluded immunosuppressive therapy also include chemotherapeutic agent use treat cancer condition , treatment associate organ bone marrow transplantation , autoimmune disease . Participant receive licensed nonlive vaccine within 14 day receipt study vaccine . Participant receive licensed live virus vaccine within 30 day prior receipt study vaccine . Prior receipt blood transfusion blood product , include immunoglobulin . Investigational drug vaccine receive within 2 month receipt study vaccine . Participation another clinical study within 42 day begin anytime duration current clinical study . History invasive pneumococcal disease ( positive blood culture , positive cerebrospinal fluid culture , sterile site ) know history culture positive pneumococcal disease . A recent febrile illness ( rectal temperature ≥38.1°C [ ≥100.5°F ] ) occur within 72 hour receipt study vaccine . History failure thrive . Participant coagulation disorder contraindicate IM vaccination . Participant his/her mother document hepatitis B surface antigenpositive . Any infant adequately follow safety accord protocol plan . Participant 's parent/legal guardian unlikely adhere study procedure , keep appointment , plan relocate study . Any reason opinion investigator may interfere evaluation require study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Invasive pneumococcal disease</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Pneumococcal conjugate vaccine</keyword>
</DOC>